[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"predictive-cancer-model\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:predictive-cancer-model":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,72,99,128],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100544091","dynamic-multi-omics-integration-model-to-predict-neoadjuvant-therapy-response-in-locally-advanced-rectal-cancer-100544091",false,"NCT06364371","Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer","A Study of the Clinical Value of Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer (T3-4NxM0)","Inclusion Criteria:\n\n1. Histologically confirmed rectal adenocarcinoma;\n2. Clinical stage T3-4NxM0, with or without positive Mesorectum Fascia(MRF), and with or without positive Extra-Mural Venous Invasion(EMVI);\n3. Preoperative staging method: All patients undergo preoperative staging with enhanced CT. Criteria for mesorectal lymph node metastasis: Short axis ≥ 10mm lymph nodes or lymph node morphology and CT characteristics consistent with typical lymph node metastasis. Preoperative chest, abdominal CT, and pelvic MRI exclude distant metastases;\n4. Absence of signs of intestinal obstruction; or relief of obstruction after proximal colon diversion surgery;\n5. No history of previous colorectal surgery;\n6. No history of previous chemotherapy or radiotherapy;\n7. No history of previous biological therapy (such as monoclonal antibodies), immunotherapy \\[such as anti-programmed cell death protein 1(PD-1) antibodies, anti-PD-L1 antibodies, anti-PD-L2 antibodies, or anti-Cytotoxic T Lymphocyte-Associated Antigen-4(CTLA-4)\\], or other investigational drug therapy;\n8. No history of previous hormonal therapy: no restrictions;\n9. Signed informed consent form.\n\nExclusion Criteria:\n\n1. Patients requiring antiarrhythmic therapy (excluding β-blockers or digoxin), symptomatic coronary artery disease, recent myocardial infarction within the past 6 months, or congestive heart failure exceeding New York Heart Association(NYHA) class II;\n2. Poorly controlled severe hypertension;\n3. History of HIV infection or active chronic hepatitis B or C (high viral DNA load);\n4. Active pulmonary tuberculosis (TB) or receiving anti-TB treatment, or having received anti-TB treatment within the past year;\n5. Other active clinically severe infections ;\n6. Evidence of distant metastases outside the pelvis preoperatively;\n7. Cachexia, organ decompensation;\n8. History of pelvic or abdominal radiotherapy;\n9. Multifocal colorectal cancer;\n10. Patients requiring management for epileptic seizures (e.g., with steroids or antiepileptic therapy);\n11. History of other malignant tumors within the past 5 years, excluding cured carcinoma in situ of the cervix or basal cell carcinoma of the skin;\n12. Substance abuse or medical, psychological, or social conditions that may interfere with patient participation in the study or assessment of study results;\n13. Presence of any active autoimmune disease or history of autoimmune disease (including but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, nephritis, hyperthyroidism, hypothyroidism; patients with vitiligo or childhood asthma that has completely resolved and does not require any intervention in adulthood may be included; patients with asthma requiring bronchodilators for medical intervention cannot be included);\n14. Vaccination with any anti-infective vaccine (e.g., influenza vaccine, varicella vaccine, etc.) within 4 weeks before enrollment;\n15. Complications requiring long-term use of immunosuppressive drugs or systemic or local administration of corticosteroids with immunosuppressive effects (dose \\> 10mg\u002Fday of prednisone or equivalent corticosteroids);\n16. Known or suspected allergy to the investigational drug or any medication administered related to this trial;\n17. Any unstable condition or situation that may jeopardize patient safety and compliance;\n18. Pregnancy or lactation in women of childbearing potential who have not taken adequate contraceptive measures;\n19. Refusal to sign the informed consent form.","ALL","18 Years","80 Years",{"count":20,"type":21},106,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to establish a dynamic multi-omics integration model for predicting pathological complete response (pCR) after neoadjuvant treatment in locally advanced (T3-4NxM0) rectal cancer, providing support for subsequent patient selection for the watch-and-wait strategy. The main question it aims to answer is:\n\nWhat is the predictive value of this model to assess individual achievement of pathological complete response (pCR) after neoadjuvant treatment? Eligible patients will be prospectively enrolled, and the clinical features of their pre-neoadjuvant treatment, during-treatment, and post-treatment preoperative will be collected and annotated.",[25,26],"Predictive Cancer Model","Pathologic Complete Response",[28,29,30,31],"Magnetic resonance imaging","ctDNA","Histopathology slide","CEA","RECRUITING","2025-12-11",{"date":35,"type":36},"2025-12-18","ACTUAL",{"date":38,"type":36},"2024-06-01",{"date":40,"type":21},"2028-06-01",{"name":42,"class":43},"Sixth Affiliated Hospital, Sun Yat-sen University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":44},"100546204","phase-3-liquid-biopsy-ctdna-guided-treatment-in-localized-pancreatic-cancer-neoadjuvant-ctx-vs-upfront-surgery-100546204","NCT06391892","Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery","Liquid Biopsy Guided Treatment in Localized Pancreatic Cancer (LIQUIPANC): Circulating Tumor DNA (ctDNA) as Precision Medicine Tool for Stratification of Neoadjuvant Chemotherapy vs. Upfront Surgery","LIQUIPANC","Inclusion Criteria:\n\n* Informed consent\n* \\>18 years old\n* localized pancreatic cancer to go for upfront surgery\n\nExclusion Criteria:\n\n* synchronous secondary malignancy\n* pregnancy","99 Years",{"count":55,"type":21},100,"INTERVENTIONAL",[58],"PHASE3","This study evaluates the clinical prognostic impact (on DFS and OS) of liquid biopsy guided treatment vs. standard of care (physicians choice) in localized pancreatic cancer (despite because of CA 19-9 levels and computed tomography, upfront surgery is recommended by tumor board). ctDNA positive patients will receive neoadjvuant chemotherapy at current gold standard physicians choice instead of upfront surgery, because of assumed high biological risk for early recurrence.",[61,62,25],"Pancreatic Cancer","Circulating Tumor Cell","2024-04-25",{"date":65,"type":36},"2024-04-30",{"date":67,"type":36},"2024-01-11",{"date":69,"type":21},"2026-12-31",{"name":71,"class":43},"Elisabethinen Hospital",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100531638","predicting-tumor-metastasis-by-employing-a-target-organprimary-lesion-fusion-radiomics-model-100531638","NCT06202404","Predicting Tumor Metastasis by Employing a Target Organ\u002FPrimary Lesion Fusion Radiomics Model","Predicting Tumor Metastasis by Employing a Target Organ\u002FPrimary Lesion Fusion Radiomics Model: a Prospective Observational Trial","Inclusion Criteria:\n\n1. ECOG performance status score 0-2;\n2. Histologically or cytologically confirmed stage III-IV NSCLC;\n3. If the baseline pathology is adenocarcinoma, driver gene testing (at least EGFR\u002FALK\u002FROS1\u002FKRAS\u002FMET) should be performed;\n4. Complete imaging data of baseline stage (contrast-enhanced MR For lung cancer, contrast-enhanced MR\u002FCT for colorectal cancer, and chest CT for breast cancer);\n5. No target organ metastasis on baseline imaging (no brain\u002Fliver\u002Flung metastasis for lung cancer\u002Fcolorectal cancer\u002Fbreast cancer, respectively);\n6. Patients received at least one systemic therapy (chemotherapy, targeted therapy, immunotherapy, etc.) and received regular follow-up;\n7. Regular follow-up during and after treatment;\n8. Life expectancy ≥6 months;\n\nExclusion Criteria:\n\n1. Patients with indeterminate pathological type;\n2. Patients without baseline imaging data before treatment;\n3. Baseline imaging examination showed that the corresponding target organ had metastasis (lung cancer\u002Fcolorectal cancer\u002Fbreast cancer corresponding to brain\u002Fliver\u002Flung metastasis);\n4. patients who cannot or refuse to receive regular imaging follow-up;\n5. Combined history of other malignant tumors;\n6. Medical examination or clinical findings or other uncontrollable conditions that the investigator considers may interfere with the results or increase the risk of treatment complications for the patient; ,\n7. Lactating or pregnant women;\n8. Receiving other long-term medications that may affect disease progression as assessed by a physician.","75 Years",{"count":81,"type":21},166,"A pre-metastatic target organ\u002Fprimary lesion fusion radiomics model was developed based on the \"soil-seed\" theory to predict comman tumor metastasis in retrospective settings. To prospectively verify the performance of the target organ\u002Fprimary lesion fusion radiomics model in predicting tumor metastasis patterns (brain metastasis in lung cancer, liver metastasis in colorectal cancer, lung metastasis in breast cancer), we designed this prospective observational trial.",[84,25],"Metastasis",[86,87,88],"metastasis","radiomics","seed and soil theory","2024-02-08",{"date":91,"type":36},"2024-02-09",{"date":93,"type":36},"2024-01-01",{"date":95,"type":21},"2027-12",{"name":97,"class":43},"Fudan University",2,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":107,"sex":16,"minAge":17,"maxAge":79,"enrollmentInfo":108,"targetDuration":110,"studyType":22,"phases":4,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":126,"locationsCount":44},"100510663","innovative-approach-to-detect-recurrent-colorectal-lesions-with-surveillance-via-mutation-analysis--clinical-phenotype-100510663","NCT05929365","Innovative Approach to Detect Recurrent Colorectal Lesions With Surveillance Via Mutation Analysis & Clinical Phenotype","Development and Clinical Utility of a New Method to Identify Patients With Risk of Recurrent Colorectal Lesions and Personalization of Their Surveillance Based on Mutation Burden and Clinical-pathological Phenotype","MTG","Inclusion Criteria:\n\n* Colorectal polyp larger than 10mm removed by colonoscopy therapeutic method (EPE, EMR, ESD)\n* Signed informed consent with the study and with colonoscopy\n\nExclusion Criteria:\n\n* FAP, HNPCC and other hereditary CRC syndromes probands\n* Colonoscopy contraindication\n* Severe acute inflammatory bowel disease\n* Severe comorbidities; likely non-compliance of the patient",true,{"count":109,"type":21},200,"5 Years","It is known that the development of colorectal adenoma is dependent on the appearance of somatic mutations in protooncogenes and tumor suppressor genes. Based on our previous mutation analyses of 120 patients with high-risk adenoma removed by enbloc resection with subsequent colonoscopy after 1 year, there is a correlation between mutation in exon 7 of the TP53 gene and risk of early metachronous lesions development. The results also indicate that mutation phenotype (mutation profile and burden) of all lesions detected on index colonoscopy can determine risk of metachronous lesions. As not all synchronous lesions were analyzed and the surveillance colonoscopy interval was less than 3 years, this assumption could not be confirmed. In this study it is planned to perform mutation analysis of all synchronous lesions in 200 patients and correlate the data with appearance of metachronous lesions after 1, 3 and 5 years. Moreover, the mutation profile of all metachronous lesions developed during the 5 years of surveillance will be determinated and compared with mutation profile of index lesions from the same localization to verify their common biological origin. This all could help personalize the surveillance program in terms of reduction of the burden on the patient and endoscopic workplaces and risk of developing colorectal cancer in a particular patient.",[25],[114,115,116,117,118,119],"phenotype","surveillance","colonoscopy","colorectal neoplasia","genetic mutation","metachronous lesions","2023-06-25",{"date":122,"type":36},"2023-07-03",{"date":124,"type":36},"2022-05-01",{"date":69,"type":21},{"name":127,"class":43},"Military University Hospital, Prague",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":151},"100376765","colo-cohort-colorectal-cancer-cohort-study-100376765","NCT04185779","COLO-COHORT (Colorectal Cancer Cohort) Study","Inclusion Criteria:\n\nGroup A\n\n* Aged ≥30 years\\* and able to give informed consent\n* Patients attending colonoscopy\n\n  * Through Bowel Cancer Screening Programme (FIT positive, Bowelscope conversion, surveillance)\n  * Through standard NHS care (most commonly due to iron deficiency anaemia, altered bowel habit, weight loss, rectal bleeding, planned polypectomy\\*\\*, those referred on basis of family history, abnormal cross-sectional imaging, polyp surveillance or post CRC surveillance)\n\n    * The age of 30 was chosen to ensure that this is a population likely to be enriched for colorectal neoplasia with neoplasia below this age uncommon \\*\\*In those attending for planned polypectomy, the results from the initial colonoscopy and the endoscopy where the polypectomy is undertaken will be summated for purposes of calculating the neoplasia profile\n\n(COLO-SPEED) Group B\n\n* Any patient attending for colonoscopy and able to give informed consent\n* ≥ 18 years old\n* Patient from the North of England\n\nExclusion Criteria:\n\nGroup A\n\n* Unable to give informed consent\n* Known polyposis syndrome\n* Previous total colectomy\n* Known colonic stricture which would limit complete colonoscopy\n* Attending for planned therapeutic procedure other than polypectomy, such as insertion of colonic stent\n* Attending for assessment of known inflammatory bowel disease (IBD) activity or for IBD surveillance\n* Patients currently recruited into an interventional CTIMP for CRC prevention\\*\n\nCOLO-SPEED (Group B) \\*\\*\n\n* Unable to give informed consent\n* Not in a centre supported by COLO-SPEED infrastructure (North of England)",{"count":135,"type":21},15000,"This is a cross-sectional study aimed at identifying factors which best predicts patients at high risk of colorectal cancer or colorectal adenomas and to develop a risk prediction model.",[138,139,140,25,141],"Colorectal Cancer","Colorectal Adenoma","Colorectal Neoplasm","Model","2020-10-19",{"date":144,"type":36},"2020-10-22",{"date":146,"type":36},"2019-12-13",{"date":148,"type":21},"2026-08-15",{"name":150,"class":43},"South Tyneside and Sunderland NHS Foundation Trust",3]